Introduction
Hematopoietic stem cells (HSC) have been among the most alluring targets for gene transfer because of their unique lifelong ability to proliferate and differentiate into all of the cell lineages in peripheral blood. It has been proposed that gene delivery to HSC could potentially ameliorate selected genetic diseases, as well as be applicable to treatment of such acquired diseases as cancer, AIDS and autoimmune and neurodegenerative disorders. Recent reports of hematopoietic stem cell plasticity, i.e., the ability to develop into cells of nonhematopoietic lineages may open new vistas for hematopoietic stem cell gene delivery.
Human HSC gene therapy clinical trials have generally yielded disappointing results, the main exception being successful treatment of severe combined immune deficiency (SCID-X1 and ADA-SCID) [1] [2] [3] . Successful gene transfer has been hampered by low transduction efficiency of human HSC because oncoretroviruses, the viral vectors usually used for this purpose, require cell division in order to integrate into host genome 4 . Primitive HSC, by contrast, are naturally quiescent 5, 6 .
To overcome this obstacle, strategies have been developed using different cytokines in various combinations that aim to elicit cell division while preserving self-renewal and differentiation potential. Achieving this aim has proven difficult. Cytokine treatment often leads to HSC differentiation, limiting pluripotency and compromising the capacity to replenish the stem cell pool. Such ex vivo treatment also interferes with bone marrow cell homing and engraftment, which are obligatory because the cultured transduced cells must be reimplanted in vivo [7] [8] [9] [10] [11] [12] [13] .
For personal use only. on . by guest www.bloodjournal.org From Lentiviral vectors have recently evoked interest because they can transduce nondividing cells including HSC 14 . However, fully quiescent G0 cells are poorly transduced by these vectors 15, 16 , so that effective lentiviral gene transfer to HSC still requires ex vivo cytokine stimulation 17 . The requisite short-term culture may also interfere with HSC engraftment upon transplantation. Nonetheless, lentiviral vectors have proven more effective than their oncoretroviral cousins in delivering genes to primitive human HSC including human SCID-repopulating cells (SRC) in NOD/SCID mice [18] [19] [20] .
However, these encouraging data from mice have not translated to higher animals.
HIV-based lentiviral vector gene transfer to primitive HSC in nonhuman primates has yielded disappointing results [21] [22] [23] [24] [25] . For these and other reasons, clinical trials of lentiviral HSC gene therapy have been long in coming. Other retroviral gene delivery systems offer promise along these lines, but await further development 26, 27 .
It may thus be useful to approach the challenge of HSC gene delivery using different paradigms, e.g., applying both novel vector systems and direct in situ gene delivery to HSC. Recombinant SV40-derived viral vectors (rSV40s) transduce nondividing cells, including neurons and hematopoietic stem cells efficiently, and achieve long-term transgene expression in vitro and in vivo [28] [29] [30] [31] , although levels of protein production tend to be lower than with other vector systems. We and others have demonstrated efficient transduction of hematopoietic progenitor cells using SV40 viral vectors ex vivo 30, 32 . In this study, we report an in vivo gene transfer approach using percutaneous intrafermoral BM injection to deliver rSV40s directly into the BM cavity. Our results 
Methods and Materials

Animals
Female Sprague-Dawley rats (125-150g) were purchased from Charles River Laboratories (Wilmington, MA). Adult female BALB/c mice were purchased from Jackson Laboratories (Bar Harbor, ME).
Protocols for injecting, bleeding and sacrificing animals were approved by the Thomas Jefferson University Institutional Animal Care and Use Committee, and are consistent with AAALAC International standards.
Recombinant SV40 vectors (rSV40) used
We used two different rSV40 vectors, constructed as described previously 33 . All rSV40 vectors are derived from large T-antigen-deleted SV40 genomes, remain free of Tag, and are thus replication incompetent. SV(Nef-FLAG) carries cDNA encoding HIV Nef protein with a C-terminal FLAG epitope tag. Expression of FLAG-fusion protein was driven by CMV-IEP 34 and was tested by flow cytometry (see below) or fluorescence microscopy (Olympus) following intracellular immunostaining. SV(BUGT), a control vector used in this study, carries the cDNA for human bilirubinuridine 5'-diphosphate-glucuronysyl transferase (BUGT), driven by two tandem SV40 early promoters (SV40-EP) 35 .
Production of rSV40 viral vectors
We have reported the general principles for making recombinant replication-
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In vivo gene transfer to bone marrow using rSV40 vectors Page 8 defective SV40 viral vectors. Briefly, the cloned SV40 genome was excised from its carrier plasmid, gel-purified and recircularized, then transfected into COS-7 cells.
These cells supply in trans the large T-antigen (Tag) and the SV40 capsid proteins, which are needed to produce recombinant replication-defective SV40 viral vectors (31) .
Crude virus stocks were prepared as cell lysates and were then band-purified by discontinuous sucrose density gradient ultracentrifugation, and titered by in situ PCR 36 .
Infectious titers of such rSV40 viral vectors are generally 10 11 to 10 12 Infectious Units (IU)/ml.
Procedure of percutaneous intrafemoral BM injection
Sprague Dawley rats were anesthetized and the region from the hip to the knee joint was shaved. The knee was flexed to 90° and a 27G-gauge needle attached to a 1 cc syringe was lodged between the condyles at the distal femur and access to the bone marrow cavity was gained using a drilling technique. 1 x 10 11 IU of SV(Nef-FLAG) viral vector in 100 µl PBS were injected into bone marrow cavity of each femur.
Control rats received SV(BUGT), administered identically. Rats were injected in staggered groups, with paired experimental and control animals.
Preparation of Lineage-negative (Lin-) cells
Murine bone marrow was prepared by flushing femurs and tibias from BALB/c mice with saline and collecting the resulting cells sterilely. Cells from several animals 
FLAG Immunostaining
Immunostaining to detect intracellular expressed FLAG epitope on Nef was performed for detection using indirect immunofluorescence. We cultured SV(Nef-FLAG) -transduced BMMNCs on glass slides over night, fixed them with 4% PFA at room temperature for 20 minutes, and permeabilized with 0.1% NP-40 at room temperature for 10 minutes. We blocked cells with 10% Donkey serum (Sigma, Saint Louis, USA) overnight and incubated them with mouse anti-FLAG IgG1 monoclonal antibody (mAb) (Sigma), followed by Alexa Fluor 488-conjugated donkey anti-mouse IgG (Molecular Probes, Eugene, OR). We analyzed slides using an Olympus inverted fluorescence photomicroscope, and digitalized images using Spot software and a Macintosh computer (Apple Computer Corp.). Photographic images were composited using Adobe Photoshop (Adobe Systems, Inc., San Jose, CA).
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Results
Transduction of Lin-cells by rSV40 vectors
rSV40s gene transfer to human and primate HSC has been reported 30 . However, effective transduction by these vectors of the equivalent rodent cell populations (Lincells) has not been documented. Antibodies to rat bone marrow hematopoietic lineage markers were unavailable, and the monoclonal antibodies against mouse bone marrow populations were of rat origin, and so of undefined reactivity vs. rat bone marrow cells.
Therefore, to evaluate rSV40 gene delivery to rodent Lin-cells, we used mouse bone marrow cells as targets.
Mouse bone marrow cells were sorted using magnetic bead separation (MACS, see 
SV40 viral vectors efficiently transduce unstimulated Rat bone marrow mononuclear cells in vitro
Before attempting intramarrow administration, we first tested whether rSV40 vectors could deliver genes to rat bone marrow mononuclear cells (BMMNCs) in vitro.
Low density BM mononuclear cells (BMMNC) were selected from rat femurs and tibias using Ficoll-Hypaque.
The freshly isolated rat BMMNCs were transduced with SV40(Nef-FLAG) at a virus:cell ratio (MOI) of 100 for 2 hours without cytokine stimulation. After
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From Page 13 transduction, cells were cultured for 3 weeks in the presence of cytokines (IL-3, IL-6 and SCF (see details in Methods and Materials)). Control cells were mock-transduced and cultured under the same conditions. On days 7 and 21 after transduction, the cultured cells were analyzed for FLAG expression using immunostaining as described in Methods and Materials. As shown in Figure 2 , FLAG expression was detected in almost all SV(Nef-FLAG)-transduced BMMNCs 7 ( Fig. 2(a) ) and 21 ( Fig. 2(b) ) days after transduction. Control cells were negative. Percentages of FLAG-expressing cells were identical in transduced cultures assayed at 7 days and 21 days, indicating that transgene expression delivered by the rSV40 viral vector persisted. Taken together, our data demonstrate that SV40 viral vectors transduce rat BMMNCs with very high efficiency and that they deliver sustained transgene expression. Original magnification, x200.
Efficient in vivo transduction of rat bone marrow cells using SV40 viral vectors
To test the transduction efficiency of bone marrow cells in vivo, four animals were injected with SV40 viral vectors at a dose of 1 x 10 11 IU/femur. Two rats were sacrificed each on day 7 and day 42 post-injection. Bone marrow cells were assayed for FLAG expression by flow cytometry after intracellular immunostaining. Figure 3 shows representative FACS scattergrams for FLAG expression in both BM leukocytes (Fig. 3a) and subpopulations (Fig. 3b) examined on day 7. Data from 6 weeks were virtually identical (not shown). Percentages of BM cells expressing FLAG ranged from 20-30%. The intensity of FLAG immunopositivity was also high. In these analyses, gating for granulocytes and nongranulocytes was based on forward scatter (FSC) and side scatter (SSC). 
High levels of in vivo transgene expression in rat PB cells after rSV40 gene delivery by percutaneous intra-marrow injection
Having therefore established that intramarrow administration allowed for gene
to bone marrow hematopoietic cells, we tested whether SV40 vial vectors given this way could transduce bone marrow progenitor cells in vivo. We used this percutaneous bone marrow injection technique in a rat model to deliver SV40 viral vectors directly into BM cavity of both femurs, and then followed peripheral blood cells for FLAG expression. Test rats received percutaneous intrafermoral bone marrow injections of SV(Nef-FLAG) at 2 x 10 11 IU/animal, as described in Methods and Materials. Control rats received SV(BUG-T), carrying human BUGT cDNA under identical conditions. All rats were followed by peripheral blood sampling every 2 to 4 weeks up to 56 weeks for FLAG expression in nucleated cells using flow cytometry following intracellular immunostaining (see Methods and Materials). Figure 4a shows the percentage of FLAG-expressing cells among PB leukocytes of SV(Nef-FLAG)-injected animals for the duration of the study averaged for all rats for each time point.
Within the first 2 weeks of injection, FLAG was expressed in between 7 and 10% of PB leukocytes, averaging approximately 9%. Interestingly, in all animals, beginning 2 weeks thence, the percentage of FLAG-expressing cells in PB leukocytes decreased gradually to its nadir of between 0.5 to 1% at week 8 after injection. These percentages then rose again at week 10, at which point they ranged from 2.8 to 7%, averaging 4.3%.
After week 12, percentages of FLAG+ cells among PB nucleated cells were relatively stable, ranging between 3.5 to 10% and averaging 6.04%, throughout the 13 month follow-up period. The sole exception was rat #4, in which FLAG expression decreased after 10 weeks and became undetectable by week 22. 
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Statistical analysis comparing all test animals vs. their paired control (SV(BUGT)-injected) counterparts for each assay point showed that the percentages of FLAG+ cells in the blood were significantly above background levels at each biweekly time point.
Although levels of statistical significance varied from week to week, the significance was always at least P < 0.05, and at most time points, P < 0.01 by Wilcoxon signed rank 
Long term Gene expression in PB multiple hematopoietic lineages
To see whether BM injection using rSV40 viral vectors transduced progenitor cells that differentiated into multiple lineages, we followed FLAG expression in granulocytes, and T and B lymphocytes as hematopoietic subpopulations in PB of injected rats over time by flow cytometry (see Methods and Materials). 
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Long term gene expression in rat BM cells
To determine levels of FLAG expression among bone marrow cells of injected rats, (Fig. 6a) and granulocytes (Fig. 6b) of these animals. As expected, percentages of FLAG expressing cells in femoral BM, the site of gene delivery, were much higher than in the PB for those animals for which both determinations were done at the time of sacrifice (Figure 7) .
In some animals, BM cells from the tibia were also assayed for FLAG expression.
Interestingly, when assayed at 16 months, there was no difference in the percentages of FLAG-expressing cells in the BM from femur and tibia (data not shown), suggesting that bone marrow progenitor cells may not be stationary within the hematopoietic system, but may migrate and redistribute among the various blood-forming areas of the We have pursued a similar strategy, except that we used rSV40 viruses to deliver a marker gene. These vectors were employed in the current study because they are capable of transducing cells in G0 with high efficiency and integrating into their genomes to provide permanent transgene expression to both parent and daughter cells. The marker transgene used, the FLAG epitope, was appended to a carrier protein, in FLAG was expressed in both granulocyte and lymphocyte PB populations throughout. These data indicate that these vectors, injected directly into the femoral bone marrow cavity in vivo, transduced cells capable of differentiating into these diverse lineages. Whether these cells were true "stem" cells is not clear, and cannot be considered to have been unequivocally established by these studies: HSC are a very low For personal use only. on October 28, 2017. by guest www.bloodjournal.org From percentage of the bone marrow cell pool (<<1%), and rodent HSC are generally considered to be lineage-negative (i.e., they lack an agreed-upon cell membrane marker), so that coexpression of FLAG + a HSC marker cannot easily be demonstrated. If they were not HSC, however, they were long-lived progenitors and capable of both dividing and differentiating into mature cells of lymphoid and myeloid series.
Although rSV40 vectors are very effective in transducing mature lymphocytes 31,44,,45 , the percentages of total cells in the blood and bone marrow that expressed both FLAG and lymphocyte markers were low, compared to granulocytes. This difference may reflect several factors. Lymphocytes are relatively long-lived, compared to granulocytes, so that the transduced lymphoid progenitors in the BM might not necessarily proliferate and differentiate in the absence of a systemic stress that would generate an increased demand for more lymphocytes. Bone marrow source(s) of lymphoid progenitors may fluctuate or change with time so that the femoral marrow may be responsible for a decreasing percentage of blood lymphocytes. It is also possible that expression of HIV-1 Nef carrier protein may have some lineage specific toxicity. Such toxicity has been found for endothelial cells 46 , but not, to our knowledge, for T cells. This issue could be further addressed by doing serial transplantation with transduced BM cells of injected animals (which was not possible in these outbred rats), or by inducing transduced hematopoietic stem or by pretreatment with cytotoxic drugs or antibodies against specific lineages to deplete circulating pools of mature cells, either before or after transduction.
Percentages of transgene expressing cells in the BM of injected rats were much
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From higher than in the PB. A second study also reported the same results 47 . Although femoral marrow, the target in this study, is only 10-15% of the total marrow pool, it is of interest to note that at 16 months post-transduction, another bone marrow site (the tibia) contained similar percentages of FLAG+ cells. These findings, together with the very high levels of (e.g.) granulocyte marking, suggest that intrafemoral marrow injection may reach more progenitor cells than simply those present there at the time of injection.
As well, resident marrow progenitors or their immature derivatives may circulate among the marrow-containing bones. Migration of HSC has been studied in transplant situations [48] [49] [50] , but this experimental system may allow for its study in resident HSC.
The levels of FLAG expression (i.e., the intensity of immunopositivity) were notably higher in the bone marrow FLAG-expressing cells than in the FLAG+ cells in the blood.
The reasons for this intriguing observation are unknown, but suggest that maturation of these cells, which coincides with their release to the circulation, may be attended by alterations in levels of gene expression and that transduced genes may be affected by this process. If others can confirm this observation, implications for bone marrowdirected gene delivery are substantial. Modifications, e.g., of promoters or other facets of the vector or expression cassette, may be necessary.
Percentages of transgene-marked cells may be further increased by multiple injections, preferably into different bone marrow sites. We attempted to inject other bones in the rat, but more distal accessible long bones (e.g., tibia) contain much less marrow than the femur, and other bones we tried (e.g., ilium, sternum) proved too fragile for our injection technique. Studies are in progress to test this issue in larger
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Repeated vector dosing may also be tried, since the majority of bone marrow cells, even in the femur, were not transduced with a single injection. Increased percentages of rSV40-transduced cells have been seen using other rSV40 vectors in vivo targeting other organs 51, 52 . In this respect, rSV40 vectors have a unique advantage: repeated studies have shown that they do not elicit detectable neutralizing immune responses, and so can be given multiple times without loss of gene delivery efficiency 53, 54 . The mechanistic basis for this observation is speculative, but may lie in the unique method of cell entry employed by these vectors [55] [56] [57] [58] [59] [60] . This lack of antigenicity and the ability to transduce nondividing cells make SV40 vectors attractive vehicles for HSC gene transfer.
In conclusion, in our present study, we demonstrated efficient and sustained in vivo gene transfer using BM injection of rSV40 vectors. Direct in vivo BM injection may be an alternative to current gene delivery approaches to the bone marrow, and SV40-derived vectors may be useful tools for this purpose.
